ArticlePharmacognosy magazine2016
Postprandial Antihyperglycemic And Antioxidant Activities of
Article in Pharmacognosy magazine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 22 citations in OpenAlex.
- Innate Immune Profile in Diabetes Mellitus Rat Treated with Acalypha Indica Extract: Focus on TLR-2, TLR-4,International journal of preventive medicine · 2026Article
- The effect of simvastatin-Journal of advanced veterinary and animal research · 2022Article
- Phytochemical Profile, Free Radical Scavenging and Anti-Inflammatory Properties ofMolecules (Basel, Switzerland) · 2021Article
- Ecofriendly ruthenium-containing nanomaterials: synthesis, characterization, electrochemistry, bioactivity and catalysis.Nanoscale advances · 2020Review
- Ethnopharmacological Inspections of Organic Extract ofEvidence-based complementary and alternative medicine : eCAM · 2019Article
- Fatty Acid Profiling andPharmacognosy magazine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundα-glucosidase inhibitors controls postprandial hyperglycemia (PPHG) by lowering sharp rise in blood glucose levels after ingestion of carbohydrate rich meal in type 2 diabetic (T2D) individuals.
objectiveIn this perspective, this study was designed to evaluate postprandial antihyperglycemic potential of AIS in maltose, sucrose, and glucose loaded streptozotocin (STZ)-induced normal and diabetic rats. As, the acute hyperglycemia at postprandial period has more triggering effect on oxidative stress, study was also aimed to evaluate the antioxidant potential of AIS on STZ-induced Albino-Wistar rats. MATERIALS AND
methodsRats were treated with AIS (300-600 mg/kg b.w.) to investigate effect of AIS in controling PPHG after carbohydrate loading. Hepatoprotective activity of AIS is evaluated in diabetic rats by treating them at the dosages 300-600 mg/kg b.w.
resultsStudies revealed 69.10 and 80.35% blood glucose-lowering effect of AIS in maltose and sucrose loaded diabetic rats in comparison with the diabetic control group. AIS recovered the liver damage caused by streptozotocin.
conclusionThe present study confirmed high potential of AIS in controling PPHG by inhibiting a-glucosidase enzyme in maltose and sucrose loaded diabetic rats. AIS also exhibited hepatoprotective activity in STZ-induced diabetic rats. Thus, AIS could be used as a nutraceutical supplement to treat T2D effectively. SUMMARY: AIS extract is effective in suppressing maltose and sucrose-induced postprandial hyperglycemic spikes in ratsAIS treat ment showed a 69.10 and80.35% blood glucose-lowering effect in maltose and sucrose loaded diabetic rats in comparison with the diabetic control group.AIS also improved the antioxidant status in diabetic rats and also has recovered the liver damage caused by streptozotocin.The α-glucosidase inhibitor isolated from AIS is a good supplement to control postprandial blood glucose level in the management of type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.